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TIMI                        - Thrombolysis in Myocardial Infarction  
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PCI              - Percutaneous coronary intervention 
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INC                          - Including       
SOB              - Shortness of breath 
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MILD LV DYS   - Mild Left ventricular dysfunction. 
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INTRODUCTION
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INTRODUCTION 
 
Cardiovascular diseases contribute 29.3 % of all deaths 
worldwide according to WHO statistics. Out of these around half of the 
deaths are due to ischemic heart diseases. In India it is the leading cause 
of death (15%) followed by respiratory infections (11 %) and 
cerebrovascular diseases (7 %). 
Cardiovascular disease continues to be the major cause of death
 
despite the
 
use of new pharmacological strategies to lower blood lipids,
 
more aggressive therapy of hypertension, and changes in lifestyle. Acute 
coronary syndromes include acute myocardial infarction
 
(MI) with ST-
segment elevation, non ST elevation myocardial infarction (NSTEMI) 
and unstable angina
 
(UA). This syndrome is a serious health problem 
because it is   
 
responsible for 20% of all medical emergency department
 
admissions with the highest risk for adverse events and death. 
      In recent times lot of advances have been made in the field of  
biomarkers for the diagnosis of acute myocardial infarction like 
Ischemia-Modified Albumin, Myeloperoxidase, Phosphorylase 
Isoenzyme BB, IL- 6 , PAPP-A and many more are under trial. 
But in the field of prognostic biomarkers only very few are 
available which includes high sensitivity CRP and initial Troponin I 
levels. 
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        In an ideal scenario patients with acute myocardial infarction 
brought immediately to a specialist care center with good expertise in 
primary percutaneous coronary intervention (PCI) as well as in 
thrombolysis, often achieve good initial results with a fully reperfused 
heart, asymptomatic patient, fully normalized ECG, early resolution of 
enzymes and a good left ventricular function in echocardiography. Even 
in such ideally treated patients on regular follow up, quality of living is 
often guaranteed but the risk for another coronary event is still many 
fold higher than the general population. 
  Often the questions from patients are, will I be symptom free ?, 
will I get chest pain again even if I take the medicines regularly,  is my 
heart working well ? Will there be any other complications? 
 Here in this study use of N- Terminal pro Brain Natriuretic 
Peptide (NT-proBNP) which is an inactive remnant of a hormonally 
active Brain Natriuretic peptide (BNP) is evaluated in predicting the 
prognosis after an acute coronary syndrome. This study intends to see 
whether its initial level of NT-proBNP taken during the first episode of 
an ACS, correlates with the risk of recurrent symptoms like angina, 
dyspnea, palpitations, recurrent hospital admissions for ACS including 
unstable angina, NSTEMI, STEMI or death in a period of 6 months after 
the first coronary event.  
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  Measurement of NT proBNP is indeed an indirect measurement 
of Brain Natriuretic Peptide itself. The former is measured as it has a 
longer half-life than hormonally active BNP. 
(1)(2)(3)
 
BNP is a natriuretic peptide that is mainly released from the 
cardiac myocytes in the left ventricular wall in reaction to stretch and 
tension of the myocardial wall. The pro hormone proBNP splits into 
BNP and the hormonally inactive remnant N-terminal proBNP by 
proteolytic cleavage and both peptides will be secreted in equimolar 
amounts into the circulation. It protects the body from plasma overload 
by inducing diuresis, natriuresis, vascular dilatation and inhibition of the 
sympathetic nervous system. 
   The half-life of BNP is around 20 minutes and the half-life of NT-
proBNP is around 120 minutes. 
(1)
 
     At present for predicting the prognosis in an acute coronary 
syndrome we rely on scoring systems like Thrombolysis in Myocardial 
Infarction (TIMI) score and initial Troponin I levels.  Few studies have 
come up with use of BNP in predicting the occurrence of cardiac failure 
in ACS patients in western population.
(13)(14)(15)
 
      As Brain Natriuretic Peptide is one of the most sensitive 
biomarker for cardiac muscle strain, this study intends to evaluate its use 
as a prognostic biomarker in patients admitted with Acute Coronary 
Syndromes in South Indian Population. 
AIMS & OBJECTIVES
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Aims & Objectives 
 
1. Study whether NT ProBNP is elevated in Acute Coronary 
Syndromes 
2. To Study whether NT proBNP levels during an Acute Coronary 
Syndrome correlate specifically with symptoms like recurrent 
angina, exertional dyspnoea,  palpitations, recurrent hospital 
admissions for ACS including Unstable Angina, NSTEMI and 
STEMI or death during the follow up. 
3. To Study whether it predicts a deteriorating left ventricular 
function, and renal function. 
  
 
 
 
 
 
 
 
 
 
REVIEW
     OF
LITERATURE
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REVIEW OF LITERATURE 
 
         Brain natriuretic peptide (BNP), also known as B-type natriuretic 
peptide is a 32 amino acid polypeptide secreted by the ventricles of the 
heart. BNP is named as such, because it was originally identified in 
extracts of porcine brain. In humans it is mainly produced in the cardiac 
myocytes of the left ventricular wall. Unlike ANP, whose major storage 
sites are in both the atria and ventricles, the major source of plasma  
BNP is the cardiac ventricles, suggesting that BNP may be a more 
sensitive and specific indicator of ventricular disorders than other 
natriuretic peptides. 
(1)(2)
  
 
Structure of NT ProBNP:  
 
6 
 
      The release of BNP appears to be in direct proportion to 
ventricular volume and pressure overload.  In reaction to stretch and 
tension of the myocardial wall the pro hormone proBNP splits into BNP 
which is hormonally active and the hormonally inactive remnant, a 76 
amino acid N-terminal proBNP (NT-proBNP) by proteolytic cleavage. 
This process occurs under the influence of integrins, structures at the Z-
disc of sarcomeres. After the stretch of these sarcomeres both peptides 
will be secreted in equimolar amounts into the circulation. 
       Circulating BNP acts as an antagonist of the renin angiotensin 
aldosterone system, and protects the body from plasma overload by 
inducing diuresis, natriuresis, vascular dilatation and inhibition of the 
sympathetic nerves system. BNP has antiremodeling and antifibrotic 
activity 
(2)
. 
           The half life of BNP is around 20 minutes and the half life of 
NT-proBNP is around 120 minutes 
(1)
. 
Natriuretic Receptors : 
1. Guanylyl cyclase-A (GC-A) also known as natriuretic peptide 
receptor-A (NPRA/ANPA) or NPR1 
2. Guanylyl cyclase-B (GC-B) also known as natriuretic peptide 
receptor-B (NPRB/ANPB) or NPR2 
3. Natriuretic peptide clearance receptor (NPRC/ANPC) or NPR3 
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BNP binds to and activates the atrial natriuretic factor receptors 
NPRA, and to a lesser extent NPRB, in a fashion similar to atrial 
natriuretic peptide (ANP) but with 10-fold lower affinity. Both atrial 
natriuretic peptide and brain natriuretic peptide bind and activate GC-A, 
whereas CNP binds and activates GC-B. The biological half-life of BNP 
however is twice as long as that of ANP and that of NT-proBNP even 
longer, making these peptides better targets than ANP for diagnostic 
blood testing. 
(7)
 
  BNP is cleared from the circulation by receptor-mediated 
endocytosis via the C-type natriuretic peptide receptor, as well as by 
enzymatic degradation via zinc-containing endopeptidases located on 
the vascular endothelial cells and in the renal tubules. Little is known on 
the exact clearance mechanism of NT-proBNP, although it has been 
suggested that the kidneys play a major role in this clearance 
(1)(2)
.    
Effect of BNP  
                      The net effect of BNP and ANP is a decrease in blood 
volume and a decrease in cardiac output. 
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Relationship of BNP/NT-proBNP and gender 
 
In healthy adults, gender differences in plasma levels of 
natriuretic peptides are found, with females having higher plasma levels. 
However, some of the studies found a gender difference for ANP/NT-
ANP and not for BNP/NT-proBNP. This might reflect the age difference 
between men and women; because BNP/NT - proBNP were shown to be 
more affected by ageing as compared to ANP/NT-ANP, this age 
difference could be more powerful in BNP/NT-proBNP. 
(22) 
 
BNP in Geriatric Age Group 
 
This relationship between age and natriuretic peptide levels is a 
consequent to age-related changes in left ventricular compliance as well 
as a decreasing GFR 
(1)(2)(7)
. Age stratification improves the ability of 
NT-proBNP to identify a high likelihood for acute heart failure (HF). 
The confirmation and exclusion cut-points for NT-proBNP will help the 
clinicians more confidently to utilize the marker in the evaluation of the 
dyspnoeic patient, preserving sensitivity for younger patients with 
suspected HF, while optimizing specificity for elderly patients. In 
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elderly non-systolic HF below the threshold for acute HF, >97% had an 
NT-proBNP value above the „rule out‟ cut-point of 300 pg/mL (7). 
    NT-proBNP levels are higher in older female subjects when 
compared with age-matched male subjects, possibly due to a higher 
prevalence of diastolic abnormalities or more significant age-related 
reductions in GFR in women. There were no gender differences in 
younger age groups. The cut-off points proposed by PRIDE study is 
1800 pg/mL for those >75 years (20). Thejus et al Study on NT proBNP 
and Atrial Fibrillation takes cutoff value of NT-proBNP for diagnosis of 
heart failure as 125 pg/ml in the below 75 years age group and 450 
pg/ml in the age group above 75 years 
(19)
. The addition of this cut-point 
is relevant, as the age-related effects on NT-proBNP results are 
significant as the average age of patients with acute heart failure is 
rising.  
 
Anemia and NT-proBNP levels 
 
Anemia is a common phenomenon in HF and is related to the 
severity of the disease. Hb was related to BNP and NT-proBNP levels 
independent of severity of HF as measured by left ventricular ejection 
fraction (LVEF). But this is debatable. Studies in patients with 
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suspected coronary artery disease showed an independent association 
between Hb and BNP levels 
(21)(1)
. Anaemia results in elevated plasma 
volume, independent of the severity of Heart Failure. 
Since BNP and NT-proBNP are released in response to ventricular 
volume overload, it is conceivable that BNP and NT-proBNP levels are 
higher in anaemic HF patients compared to non-anaemic HF patients. 
Additionally, patients with anaemia and renal dysfunction showed 
higher BNP and NT-proBNP levels when compared to anaemic patients 
without renal dysfunction 
(21)
. Renal dysfunction was found to be a 
major cause of anaemia in HF patients, mediated by an erythropoietin 
production deficiency in the kidneys. 
 
BNP in Acute Coronary Syndromes : 
      BNP has usefulness as a prognostic marker among patients with  
acute myocardial infarction. BNP has prognostic value across the full 
spectrum of patients with ACS, including those with UA/NSTEMI. 
(1)(13)(14)(15) 
  In OPUS-TIMI 16, patients with elevated levels of BNP (>80 
pg/ml) or  NT-proBNP had a two to threefold higher risk of death by 10 
months 
(29)
. This finding was confirmed in the TIMI 11 and TACTICS-
TIMI 18 trials. Together, these data suggest that measurement of NT-
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proBNP in patients presenting with UA/NSTEMI adds importantly to 
our current tools for risk stratification 
(29)
.
 
Both the European Society of Cardiology and HFSA/AHF 
guidelines suggest that BNP assays are a useful adjunct to clinical 
assessment 
(29)
.  
“Breathing Not Properly” a multinational study demonstrated that 
BNP was able to distinguish dyspnoea caused by heart failure from that 
caused by pulmonary disease with a high degree of predictive power and 
it was the strongest predictor in multiple logistic regression analysis of 
the diagnosis of heart failure 
(9)
. In addition, this study was able to 
demonstrate the use of a cut-off 100 mg/dl for a normal NT-proBNP. 
The BNP test alone had a diagnostic accuracy of 81.2 percent, compared 
to 74.0 percent for clinical judgment alone. Although it may seem 
disconcerting that the addition of the physician assessment to the BNP 
measurement only barely improved diagnostic accuracy to 81.5 percent, 
the standard for diagnosis in this trial remained the clinical assessment 
by cardiologists, reviewing the totality of the clinical information. This 
trial established the role of BNP testing in the assessment of dyspnea in 
the emergency setting, and in general a BNP value of less than 100pg/ml 
is considered to have a high negative predictive value, whereas 
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concentrations greater than 400pg/ml have high positive predictive 
value for heart failure as the etiology of the dyspnoea 
(8)(9)(10)
. 
Given the larger mass of ventricle rather than atrial myocardium, 
the total amount of mRNA for BNP is higher in the ventricles than the 
atria. Natriuretic peptides are released early after STEMI, peaking at 
about 16 hours 
(13)(14)
. Evidence exists that natriuretic peptides released 
from the left ventricle during STEMI originate both from the infarcted 
myocardium as well as the viable noninfarcted myocardium 
(1)(18)
. The 
rise in BNP and N-terminal pro-BNP levels after STEMI correlates with 
infarct size and regional wall motion abnormalities
(14)
. Patients with 
anterior infarction, lower cardiac index and more significant congestive 
heart failure after STEMI have higher levels of N-terminal pro-BNP and 
BNP and such elevations correlate with a worse prognosis 
(18 )
 . 
Measurement of natriuretic peptides can provide useful 
information both early and late in the course of STEMI 
(19)
. Patients with 
elevated levels 6 hours after the onset of symptoms have a marked 
increase in mortality even after adjusting for other known prognostic 
indicators.
 
Conversely, patients with persistently elevated levels at 3 to 4 
weeks after STEMI have an increased risk of cardiac-related mortality 
over the ensuing 5 to 10 years. 
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Several studies have shown that BNP and NT-proBNP levels 
have powerful prognostic value for death and MI in patients with Non 
ST Elevation Acute Coronary Syndromes , independent of markers of 
myocardial necrosis or inflammation
(1)(14)(15) 
. The FRISC-II trial (144) 
found that BNP levels predicted the benefit of revascularization, but 
there was no such association in TACTICS - TIMI-18
(29)
. Serial BNP 
measurements can be used for dynamic risk profiling. Patients with 
normal troponin levels and low BNP levels are at very low risk of 
cardiovascular events 
(29)
. 
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Clinical significance of BNP in Heart Failure 
       Both BNP and NT-proBNP levels in the blood are used for 
screening of acute CHF. The plasma concentrations of both BNP and 
NT-proBNP are also typically increased in patients with asymptomatic 
or symptomatic left ventricular dysfunction. BNP accurately reflects 
current ventricular status. BNP is an independent predictor of high LV 
end-diastolic pressure and is more useful than ANP or norepinephrine 
levels for assessing mortality risk in patients with heart failure. 
(1)(10)(11)(28) 
 
Reference: Braunwalds Textbook of Cardiology 7
th
 edition. 
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For patients with Congestive Cardiac failure, BNP levels of more 
than 100 pg/mL have better than a 95% specificity and greater than a 
98% sensitivity when comparing patients without heart failure to all 
patients with heart failure
(1)
. 
For patients with Congestive Heart Failure, BNP values will be 
above 100 pg per millilitre 
(11)
. The Achilles heel of the NT proBNP 
molecule is the overlap in kidney disease in the heart failure patient 
population.  
The BNP test is used as an aid in the diagnosis and assessment of 
severity of congestive heart failure. Natriuretic peptide concentrations 
correlate with filling pressures and both admission and pre-discharge 
BNP concentrations are predictive of outcomes 
(24)
. The shorter half-life 
of BNP and the substantial renal clearance of NT-proBNP support the 
selection of the BNP assay for this potential diagnostic use. Changes in 
serial measures of BNP are predictive of outcomes in patients with 
AHF, beyond clinical and echocardiographic assessments and clinical 
studies are currently ongoing to assess the utility of serial inpatient BNP 
measures.  
Hullsman-Berger et al found that using NT-proBNP measurement 
as a guide to intensive patient management, resulted in better clinical 
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outcome than multidisciplinary care alone in patients after 
hospitalization for heart failure 
(26)
. In a multi-institutional trial, 278 
patients were randomized to NT-proBNP   guided intensive 
management (BM), multidisciplinary care, or usual care. After 12 
months, patients in the BM group had fewer days of heart failure 
hospitalization (488 d) than patients in the multidisciplinary care group 
(1,254 d) or usual care group (1,588 d) (p < 0.0001 for both). In 
addition, first heart failure rehospitalization was lower with BM than 
multidisciplinary care (28% versus 40%, respectively and p value was 
0.06. The combined end point of death or heart failure rehospitalization 
was lower in the BM group (37%) than in the multidisciplinary group 
(50%; p < 0.05). The death rate was 22% in both the BM and 
multidisciplinary groups, but 39% in the usual care group (p < 0.02) 
(26)
. 
Pleural Effusion is common in cardiac failure. A pleural fluid N-
terminal pro-brain natriuretic peptide more than 1500 pg/mL is virtually 
diagnostic of an effusion secondary to congestive heart failure
(4)
. 
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Acute Dyspnoea Clinical Stratification with BNP levels 
 
Diagram showing clinical stratification according to BNP levels. 
Reference: Topol Textbook of Cardiology 3
rd
 Edition 
(3)
. 
NT-proBNP is cost-effective in the diagnosis and management of 
dyspnoeic patients in the emergency room 
(3)
. 
Dyspnoea 
Rales 
Raised JVP 
Rales  
Pedal Oedema 
S3 
 
Blood Test  
ECG 
Chest X Ray 
Echocardiography 
BNP < 100 pg/ml 
Unlikely to be 
Acute Heart Failure 
Evaluate for other 
Etiologies  
(ie. pneumonia ) 
BNP 100 - 500 pg/ml 
Rule Out 
Pulmonary Embolism 
Pulmonary Hypertension 
Renal Failure 
Further imaging 
and testing  
warranted 
BNP > 500 pg/ml 
High likelihood of 
Acute Heart Failure 
Correlate Clinically 
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Cardiac Examination  
  S3 gallops or third heart sounds are detected in approximately 11 
to 34 percent of patients admitted with Acute Heart Failure.
 
 An S3 is 
fairly specific as an indicator of LV systolic dysfunction, and correlates 
with BNP levels.  
(1) 
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BNP and Incidence of Atrial Fibrillation (AF) 
 
Framingham Heart Study showed elevated BNP levels to be 
predictive of atrial fibrillation (AF), cardiovascular outcomes, and death. 
Just 68 subjects developed AF during the longitudinal study of men and 
women >65 years selected from four US communities. The group notes 
that NT-proBNP remained the strongest predictor of incident AF after 
adjustment for other variables including age, sex, medication use, blood 
pressure, echocardiographic variables, diabetes mellitus, and heart 
failure. Asselberg et al found that in the general population, elevated 
NT-proBNP levels at baseline predicted the development of AF when 
reassessed at 4 years 
(27)
. The baseline median level was 62.2 pg/ml, in 
those who eventually developed atrial fibrillation compared to 35.7 
pg/ml in those who did not. The difference was found to be highly 
significant statistically (p = 0.001). Values above the 80th percentile (97 
pg /ml in women and 60 pg/ml in men) were associated with an  
odds ratio of 2.65 for the occurrence of AF. Mollmann et al  
found that baseline NT-proBNP above  900 pg/ml significantly predicts 
(p<0.05) persistence of AF at 4 weeks after DC version of lone atrial 
fibrillation
 (19)
. 
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NT ProBNP in Pulmonary Embolism  
Elevations of NT-proBNP and BNP indicate myocardial stretch 
caused by right ventricular pressure overload. These patients also have 
an increased risk of a complicated hospital course, with a higher 
likelihood of recurrent pulmonary embolism, respiratory failure 
requiring mechanical ventilation, hypotension requiring vasopressors 
and death 
(41)(43)(51)
.
 
BNP in Cardiomyopathy  
 
BNP levels were proposed as a test to discriminate between 
restrictive cardiomyopathy and constrictive disease, with concentrations 
approximately five times greater in the former compared with the latter. 
(2)(3)(67)
 
 
BNP in Aortic Stenosis  
 
BNP and NT-proBNP are elevated in proportion to severity of AS 
and symptomatic status 
(1)(23)
. NT proBNP decreases after successful 
aortic valve replacement surgery. BNP serum level above 66 pg/mL 
detected symptomatic patients and those at risk for cardiovascular death.  
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Renal function and BNP/ NT- proBNP levels 
 
Elevated levels of BNP were also independently related to renal 
dysfunction 
(32)
.This difference may be explained by differences in 
clearance as  NT-proBNP is mainly cleared from the blood by the 
kidneys, while BNP is   cleared mainly by neutral endopeptidases and 
natriuretic peptide clearance receptors. 
  This implies that the influence of renal dysfunction should be 
more pronounced on NT-proBNP levels compared to BNP levels. 
Implications for clinical practice indicate that haemoglobin and renal 
function should be taken into account when interpreting the elevated 
levels of BNP and NT-proBNP.  
CKD influences the levels of B-type natriuretic peptide. In 
general, when the eGFR is less than 60 ml/min/1.73 m
2
, a higher BNP 
cut off point of 200 pg/ml should be used in the diagnosis of heart 
failure. It is now well recognized that CKD (eGFR < 60 ml/min/1.73 
m
2
), when present in patients with HF, independently predicts poor 
outcomes 
(32)(51)
. Brain natriuretic peptide (BNP) antagonizes the renin 
angiotensin system and angiotensin II, and may serve as a biomarker of 
response to renal revascularization.  
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 Silva et al. measured NT ProBNP in patients with uncontrolled 
hypertension and RAS (70 percent diameter stenosis), hypertension 
improved in 77 percent of those with elevated BNP levels, compared 
with group of five patients with a baseline BNP level less than or equal 
to 80 pg/ml (P = 0.001). If the BNP level fell more than 30 percent after 
successful stent placement, 94 percent (16 of 17 patients) had 
improvement in their blood pressure control 
(51)
.  
     But BNP with its physiological effects
 
of vasodilators, diuretic, 
and natriuretic action do not appear to be sufficient
 
to prevent the 
disease progression to Cardiorenal Syndrome Type II. 
 
NT proBNP in severe sepsis and septic shock 
 
NT-proBNP values are frequently increased in severe sepsis and 
septic shock. Values are significantly higher in nonsurvivors than 
survivors. NT-proBNP on day 3 in the intensive care unit is an 
independent prognostic marker of mortality in severe sepsis 
(68)
. 
NT-proBNP Elevations in Adult Respiratory Distress Syndrome 
NT-proBNP levels are elevated among patients with ARDS in a 
range typically considered consistent with heart failure. NT-proBNP 
concentrations are strongly associated with morbidity and mortality in 
ARDS 
(69)
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NT - proBNP  Predicts  Stroke Risk 
 
NT-proBNP is an independent marker of stroke risk
(34)(35)
, while 
other traditional risk factors like hypertension, left ventricular 
dysfunction were found not to be independent predictors. NT-proBNP 
was much better to point out which of the patients had a high risk for 
these cardiovascular diseases. According to Pedersen F, et al. 
(34)(35)
, 
potential prognostic factors for stroke, including age, gender, systolic 
and diastolic blood pressure, atrial fibrillation, and NT-proBNP, were 
evaluated using Cox proportional hazards analysis. The investigators 
showed that NT-proBNP was a strong independent predictor of stroke 
risk in this population with hazard ratio 4.1. 
 
Atrial Natriuretic Peptide 
  
     Atrial Natriuretic Peptide (ANP) is closely related to BNP and 
CNP (C-type natriuretic peptide). All share the same amino acid ring. 
ANP was discovered in 1981 by a team in Kingston, Ontario, Canada.  
     ANP or atrial natriuretic factor (ANF) or atrial natriuretic hormone 
(ANH), or atriopeptin, is a powerful vasodilator, and a polypeptide 
hormone secreted by heart muscle cells. It is involved in the homeostatic 
24 
 
control of body water, sodium, potassium and adipose tissue. ANP is 
produced, stored and released by the cardiac myocytes in the atria of the 
heart 
(1)(2)(3)
. 
  
ANP is secreted in response to 
1. Atrial distension or stretching of the vessel walls as in myocardial 
infarction      or aortic stenosis. 
2.  Sympathetic stimulation of β-adrenoreceptors 
3.  Hypernatremia  
4. Angiotensin-II 
5. Endothelin  
6. Exercise 
ANP secretion increases in response to immersion of the body in 
water, which causes atrial stretch due to an altered distribution of 
intravascular fluid.  
Surface receptors of natriuretic peptides.  
1. Guanylyl cyclase-Also known as natriuretic peptide receptor-A   
(NPRA/ANPA) or NPR1 
2. Guanylyl cyclase-B (GC-B) also known as natriuretic peptide 
receptor-B (NPRB/ANPB) or NPR2 
3. Natriuretic peptide clearance receptor (NPRC/ANPC) or NPR3 
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The vast majority of natriuretic peptide-dependent effects are 
mediated by elevations of intracellular cGMP concentrations. NPR-C 
functions mainly as a clearance receptor by binding and sequestering 
ANP from the circulation. All natriuretic peptides are bound by the 
NPR-C. Atrial natriuretic peptide and brain natriuretic peptide bind and 
activate GC-A 
 
Physiological effects 
ANP cause a reduction in blood volume and therefore a reduction 
in cardiac output and systemic blood pressure. Lipolysis is increased and 
renal sodium reabsorption is decreased. The overall effect of ANP on 
the body is to counter increases in blood pressure and volume caused by 
the renin-angiotensin system 
(1)
.  
 
Renal Effects 
 Dilates the afferent glomerular arteriole, constricts the efferent 
glomerular arteriole, and relaxes the mesangial cells. Thus 
increasing the glomerular filtration rate , resulting in greater 
excretion of sodium and water. 
 Increases blood flow through the vasa recta which will wash the 
solutes out of the medullary interstitium. The lower osmolality of 
the medullary interstitium leads to less reabsorption of tubular 
fluid and increased excretion. 
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 Decreases sodium reabsorption in the proximal convoluted tubule 
and cortical collecting duct of the nephron via cGMP dependent 
phosphorylation of  Epithelial sodium Chanel (ENaC). 
 Inhibits renin secretion, thereby inhibiting the renin-angiotensin 
system. 
 Reduces aldosterone secretion by the adrenal cortex. 
Vascular 
          Relaxes vascular smooth muscle in arterioles and venules. 
Cardiac 
 Inhibits maladaptive cardiac hypertrophy 
Adipose tissue 
 Increases the release of free fatty acids from adipose tissue. 
Plasma concentrations of glycerol and nonesterified fatty acids 
are increased by IV infusion of ANP in humans. 
Degradation 
Regulation of the effects of ANP is achieved through gradual 
degradation of the peptide by the enzyme neutral endopeptidase (NEP).  
C – Type Natriuretic Peptide: 
C – type Natriuretic Peptide (CNP), encoded by a gene 
symbolized NPPC. The biologically active CNP consists of 22 amino 
acids. Unlike ANP and BNP, CNP does not have direct natriuretic 
activity. CNP was observed to be a selective endothelium-independent 
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venodilator compared to ANP. This is because CNP is a selective 
agonist for the B-type natriuretic receptor (NPRB) whereas ANP and 
BNP are selective for NPRA
(1)
. 
 
 
Other natriuretic factors 
In addition to the mammalian natriuretic peptides (ANP, BNP, 
CNP), other natriuretic peptides with similar structure and properties 
have been isolated elsewhere in the animal kingdom. Tervonen (1998) 
described a salmon natriuretic peptide known as salmon cardiac peptide, 
while dendroaspis natriuretic peptide (DNP) can be found in the venom 
of the green mamba, a species of African snake  
Pharmacological modulation 
Neutral endopeptidase (NEP) is the enzyme that metabolizes 
natriuretic peptides. Several inhibitors of NEP are currently being 
developed to treat disorders ranging from hypertension to heart failure. 
Most of them are dual inhibitors. Omapatrilat (dual inhibitor of NEP and 
angiotensin-converting enzyme) developed by BMS did not receive 
FDA approval due to angioedema safety concerns. Other dual inhibitors 
of NEP with ACE/angiotensin receptor are currently being developed by 
pharmaceutical companies.  
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Nesiritide  
B-type natriuretic peptide, discussed above as a diagnostic tool, is 
also be used in pharmacological doses for the treatment of AHF 
(1)(2)
. 
Nesiritide (recombinant human BNP) is identical to the endogenous 
peptide and causes potent vasodilation in the venous and arterial 
systems including coronary vasculature. It also produces significant 
reductions in venous and ventricular filling pressures and a mild 
increase in cardiac output, with subsequent improvement in symptoms 
of dyspnoea. As with other vasodilators, nesiritide may reduce diuretic 
requirements. Nesiritide is indicated for treatment of patients with 
acutely decompensated congestive heart failure who have dyspnoea at 
rest or with minimal activity. It should not be administered for the 
indication of replacing diuretics, enhancing diuresis, protecting renal 
function, or improving survival. A bolus of 2 mg/kg followed by a 0.01 
mg/kg/min infusion is the recommended starting dose for nesiritide. 
Nesiritide has clear effects on hemodynamics and is readily 
administered with limited need for frequent dose adjustments and an 
absence of tolerance, but its high cost, lack of clear clinical benefit 
beyond other less expensive and more readily titratable agents, and 
potential safety concerns, including increased mortality,
 
have limited  
its use. 
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Evaluation Left Ventricular Systolic Function 
  
Left ventricular size can be assessed from M – mode 
measurements of the left ventricular internal diameter (LVID). The cube 
formula is used to calculate left ventricular volume 
(1)(2)(3)
.  
Left Ventricular Volume = π/3 x LVID3 
Calculation of Ejection fraction  
Ejection fraction (EF) is the fraction of blood pumped out of 
ventricles with each heartbeat. The end-diastolic (EDV) and end-systolic 
volumes (ESV)   are measured by the cube formula in M mode 
echocardiography 
(1)(2)
. Stroke volume is the difference between the 
EDV and ESV. 
    EF = (EDV – ESV) / (EDV) % 
Grading of Left Ventricular Ejection Fraction 
(1)
 
Normal :     65 ± 8 % 
Satisfactory :    45% – 55 % 
Mild LV dysfunction :   35% – 45% 
Moderate LV dysfunction :  25% - 45 % 
Severe LV dysfunction :   < 25 % 
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Killip classification  
Killip classification is a system used in acute myocardial 
infarction in order to risk stratify them. Individuals with a low Killip 
class are less likely to die within the first 30 days after their myocardial 
infarction than individuals with a high Killip class 
(42)
. 
 
Killip class I includes individuals with no clinical signs of heart failure. 
Killip class II includes individuals with rales or crackles in the lungs, an 
S3, and elevated jugular venous pressure. 
Killip class III describes individuals with frank acute pulmonary 
edema. 
Killip class IV describes individuals in cardiogenic shock or 
hypotension (measured as systolic blood pressure lower than 90 mmHg) 
and evidence of peripheral vasoconstriction like oliguria, cyanosis or 
sweating. 
The Killip-Kimball classification has played a fundamental role in 
classic cardiology, having been used as stratifying criteria for many 
other studies. Worsening Killip class has been found to be 
independently associated with increasing mortality 
(42 )
.  
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Thrombolysis in Myocardial Infarction risk score for unstable 
angina or non-ST ( TIMI Score ) 
Thrombolysis in Myocardial Infarction (TIMI) Risk Score for 
unstable angina or non-ST-elevation myocardial infarction (NSTEMI) is 
a clinical prediction rule that was originally developed to predict the 
likelihood of morbidity in patients with unstable angina or NSTEMI. 
(1)(29)(5)
 
The TIMI Risk Score for unstable angina or NSTEMI has also 
been used to detect patients with chest pain who are at increased risk of 
acute coronary syndrome. 
(5) 
Calculation  
Single point is given to each of the parameters 
 65 years of age or older  
 At least 3 risk factors for coronary artery disease (family history 
of   coronary heart disease, hypertension, hypercholesterolemia, 
diabetes, current smoking)  
 Prior coronary stenosis of 50% or more  
 ST-segment deviation on electrocardiogram at presentation  
 At least 2 Anginal events in prior 24 hours  
 Use of aspirin in the last 7 days  
 Elevated serum cardiac markers either Troponin T or CPK-MB 
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Interpretation  
The risk of death, myocardial infarction or urgent myocardial 
revascularization is according to the number of points: 
 0-1 point:    5%  
 2 points:      8%  
 3 points:    13%  
 4 points:    20%  
 5 points:    26%  
 6-7 points: 41%  
Among patients with unstable angina or NSTEMI, those with a 
TIMI risk score of 3 or more may benefit from invasive management 
(PTCA) according to the TACTICS randomized controlled trial  
(29)
.
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TIMI Risk Score for ST-Elevation Myocardial Infarction 
(STEMI) 
        The TIMI risk score for ST elevation is based upon data from 
15,000 patients with an ST segment elevation myocardial infarction 
eligible for fibrinolytic therapy. It is a simple arithmetic sum of eight 
independent predictors of mortality 
(29)
. 
TIMI Risk Score for STEMI 
Historical 
   Age 65-74 
   75 and above 
2 points 
3 points 
   Diabetes Mellitus / Hypertension or Angina 1 point 
Examination 
   Systolic Blood Pressure  < 100 3 points 
   Heart Rate  > 100 2 points 
   Killip II-IV 2 points 
   Weight  <  67 kg 1 point 
   Anterior ST Elevation or Left Bundle Branch Block 1 point 
   Time to treatment  >  4 hours 1 point 
   Risk Score = Total (0-14) 
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The risk score is a weighted integer score based upon clinical risk 
indicators at presentation. For each patient, the score is calculated as the 
sum of points for each risk feature present (range 0–14). The risk score 
was developed using multi-variable methods. 
  
METERIALS & METHODS
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MATERIALS AND METHODS 
 
Study Design: 
                           Prospective  Observational Study. 
Study Population: 
                           Patients less than 60 years of age admitted with Acute 
Coronary Syndromes in Medical Ward, GGH, Chennai, were taken into 
study  
Inclusion Criteria: 
Patients with Acute Coronary Syndromes with no prior 
history of cardiac disease. 
                          Unstable Angina , NSTEMI , STEMI. 
                          Age less than 60 years. 
Exclusion Criteria: 
 Age more than 60 yrs.  
Patients with Valvular Heart Disease 
  Patients with Anemia 
Patients with Renal Failure 
Ethical Clearance: Obtained. 
Informed Consent: Obtained from all patients. 
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Methodology 
          A total of 70 patients with acute coronary syndromes were 
identified over a period of May 2010 to December 2010, according to 
the above criteria and were included in the study. Of these only 52 
patients turned up for follow-up and participated in the study. Rest was 
omitted from the study. 
      A questionnaire was prepared. Noted the age, sex, address, phone 
number of the patient ,phone number of the relatives and in case the 
family had no phone , number of neighbours were recorded. Primary 
complaints like angina, dyspnoea, symptoms of cardiac failure were 
recorded. Risk factors for coronary artery disease like diabetes mellitus, 
systemic hypertension, smoking, hyperlipidemia, renal failure and other 
complaints if any were noted. Clinical examination included a detailed 
general examination including vital signs and systemic examination of 
cardiac, respiratory, gastrointestinal, and nervous systems. Killips Class 
was recorded if the patient was in acute MI. In NSTEMI,STEMI and 
unstable angina, TIMI scoring was also calculated. 
Laboratory Investigations: 
Blood urea and serum creatinine were used to rule out frank renal 
failure. 
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Electrocardiogram was taken to look for ST elevation or new onset left 
bundle branch block identified by comparison with previous ECG if 
available. 
In all cases an initial Echocardiography was obtained to assess the 
left ventricular function and ejection fraction.  
      Within 2 to 24 hours of the onset of symptoms, NT-proBNP 
levels were measured in blood with Rapid NT proBNP Assay Kit.  
Description of the NT proBNP Rapid Assay Kit : 
The strips are coated with canine antibodies to human NT pro 
terminal end of Brain Natriuretic Peptide. It is a semi quantitative assay 
and it gives the measurement as < 100 pg / ml , 100 – 500 pg/ml and  > 
500 pg/ml. Values below 100pg/ml was considered as minimal or 
insignificant and values above 100 pg/ml was considered significant. 
Significant values in the range of 100 – 500 pg/ml is taken as 
moderately elevated and values above 500 pg/ml were taken as 
markedly elevated.  
During subsequent visits: 
All patients were asked for any recurrent symptoms like angina, 
palpitations, dyspnoea, any rehospitalization for cardiac problems 
including unstable angina , NSTEMI or STEMI in a period of 6 month 
follow up. 
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All patients were asked to come for a repeat Echocardiogram for 
assessing the left ventricular function and compared with the previous 
echocardiographic findings at the time of admission. In all patients renal 
function tests were repeated during the follow up. If the patients did not 
come for the follow up ,the patients or the relatives were contacted 
through phone or post to enquire about the further developments and to 
get information regarding rehospitalization and death elsewhere.  
 
Investigations : 
 
Parameter Method 
ECG 12 lead ECG 
Urea GLDH/urease 
Creatinine Picrate method 
Haemoglobin Acid Haematin Method 
Troponin T or CPK -MB Hs method 
NT ProBNP Elecsys Rapid Assay 
Echocardiography  
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Normal Values 
Parameter Normal Values 
Urea 7 – 20 mgs/dl 
Creatinine M: 0.6 – 1.2mg/dl F 0.5 –.9mg/dl 
Echocardiography 
Ejection Fraction  
Normal  > 55 % 
Troponin T 
MI cut off level 
0.0 to 0.01ng /ml 
> 0.1 ng / ml 
CPK -  MB 0 – 5.5 ng / ml 
NT ProBNP 
Significant Cut Off Level in  (<  60 years age ) 
 
> 100 pg / ml 
 
 
Statistical Analysis: 
Statistical analysis was done with  
1. SPSS software version 19  
2. Microsoft Excel 2010. 
 
Conflicts of interest: None 
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OBSERVATIONS  &  RESULTS 
 
STUDY POPULATION CHARACTERISTICS 
Study population included 52 patients admitted Acute Coronary 
Syndromes who never had history of any cardiac problems prior. All 
patients are under the age of 60. Youngest of them was 39 and the oldest 
person was 59 years of age. Average Age was 50.3 and median age was 
51. As the levels of NT proBNP in elderly individuals tend to be 
elevated physiologically they are excluded from the study. Anemic and 
renal failure patients are also excluded. Out of 52, there were 38 male 
and 14 female patients. There were 14 Unstable Angina cases, 3 
NSTEMI and 35 STEMI cases. 
 
 
Figure 1: Category distribution of ACS patients. 
Study Population 
Unstable Angina
NSTEMI
STEMI
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Blood was taken 2 to 24 hours after the onset of symptoms for 
measurement of NT proBNP. Values were classified according to the 
Elecsys rapid assay kit reference value and recorded as below 100 pg/ml 
or minimal (not significant), between 100 to 500 pg/ml which was taken 
as moderately elevated (significant) and values above 500 pg/ml which 
was taken as markedly elevated (significant).  
 
Levels of NT proBNP in various Acute Coronary Syndromes 
 
 
 
 
 
 
NT ProBNP 
Levels 
Unstable 
Angina 
% NSTEMI % STEMI % 
Normal 
(<100pg/ml) 
6 42.8 1 33.3 7 20 
Significant 
Elevation 
(>100pg/ml) 
8 57.2 2 66.6 28 80 
Total No: 
Patients 
14  3  35  
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Figure 2: Showing incidence elevated NT proBNP level in various ACS 
 
Here 80 % of patients with STEMI have elevated BNP levels and 
those with NSTEMI (66.6 %) and Unstable Angina (57.2 %) had lesser 
incidence of elevated NT proBNP. This was correlating with 
observations in other studies like James S K, Lindahl et al. GUSTO 
IV
(13) 
and  Fragmin and fast Revascularisation during Instability in 
coronary artery disease (FRISC)-II
)(15)
. 
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Gender and NT ProBNP levels. 
 
Gender and NT ProBNP Levels 
 
Figure 3: Percentage of male and female patients with elevated NT proBNP 
As p value is 1.000 (>0.05) there was no correlation between gender and 
NT proBNP levels in the study group of patients under the age of 60 
years with ACS.  
 
 
0 20 40 60 80 100
Male
Female
Elevated > 100 pg/ml
<100 pg /ml
Gender and NT 
ProBNP Levels 
NT ProBNP Levels 
P Value (Fisher's 
Exact Test) Not 
elevated 
Elevated 
Male 
(Percentage) 
10 28  
(26.3%) (73.7%) 
 
 
 
1.000 
  
Female 
(Percentage) 
 
4 
 
(28.6%) 
10 
 
(71.4%) 
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Cardiac Enzymes and NT ProBNP Levels 
Cardiac Enzymes and NT proBNP 
Levels 
 
 
 
NT proBNP Levels Total 
P 
Value Not 
elevated 
Elevated 
NT 
ProBNP 
 
Elevated 
  
  
  
Count 9 26 35  
% within Cardiac 
Enzymes 
(25.7%) (74.3%) 
(100.0
%) 
 
% within NT proBNP 
Levels 
[64.3%] [68.4%] [67.3%] 
1.000 
  
Normal 
  
  
  
  
Count 5 12 17  
% within Cardiac 
Enzymes 
(29.4%) (70.6%) 
(100.0
%) 
 
% within NT proBNP 
Levels [35.7%] [31.6%] [32.7%] 
 
                                                    
Total 
  
  
Count 14 38 52  
% within Cardiac 
Enzymes 
(26.9%) (73.1%) 
(100.0
%) 
 
% within NT proBNP 
Levels 
[100.0%] 
[100.0%
] 
[100.0
%] 
 
 
RESULT  
Study showed that there is no significant correlation (as P value is 
1.0)  between cardiac enzymes and  NT proBNP levels. This is expected 
as NT-proBNP is elevated in unstable angina in addition to ST elevation 
myocardial infarction and NSTEMI. So this support the fact that they 
are independent variables even though NT proBNP is elevated in MI 
similar to CPK MB and Troponin T 
(1)(2)(3)
. 
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NT proBNP as a Prognostic Biomarker 
 
 Main aim of the study was evaluating the role of NT proBNP 
levels in an ACS patient for predicting the prognosis of an Acute 
Coronary Event in a 6 month follow up for any symptoms of recurrent 
angina, palpitations, dyspnea, rehospitalzations including unstable 
angina, Non ST elevation MI, STEMI, deterioration of  left ventricular 
function, deterioration of renal functions and  death. 
      
   This is the summary of the results in follow up period of 6 months 
 
Recurrent    Symptoms   in   follow   up 
NT ProBNP 
Levels 
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<100 pg/ml 3 1 0 1 2 0 1 0 
100-500 pg/ml 13 5 12 11 12 3 3 2 
Above 500pg/ml 14 8 10 09 11 3 9 5 
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Figure 4: Showing NT ProBNP levels and occurrence of recurrent symptoms as percentiles in the follow 
up 
 
All the recurrent symptoms in the follow up like angina, 
palpitation, hospital admissions for unstable angina and NSTEMI, 
development of left ventricular dysfunction, deterioration of renal 
functions, recurrent ST elevation myocardial infarction and death were 
more common in patients with initial NT proBNP levels more than 100 
pg/ml. There was no mortality in patients with NT proBNP levels below 
100 pg/ml. It was noted that none of the patients with NT proBNP level 
below 100 pg/ml, progressed to renal failure. 
In depth analysis of each outcome is done and the result was 
evaluated. 
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NT ProBNP Level Elevation and Recurrent Angina 
  
 
 NT ProBNP Levels 
Elevation 
  
  
  
Angina Total P 
Value 
Yes No   
< 100 pg/ml (Minimal) 
  
  
  
  
Count 3 11 14  
 
 
 
 
 
 
 
0.002 
% within NT ProBNP 
Levels Elevation (21.4%) (78.6%) (100.0%) 
% within Angina [10.0%] [50.0%] [26.9%] 
 100-500 pg/ml(Moderate) 
  
  
  
  
Count 14 9 23 
% within NT ProBNP 
Levels Elevation (60.9%) (39.1%) (100.0%) 
% within Angina [46.7%] [40.9%] [44.2%] 
 >500 pg/ml (Marked) 
  
  
  
  
Count 13 2 15 
% within NT ProBNP 
Levels Elevation (86.7%) (13.3%) (100.0%) 
% within Angina [43.3%] [9.1%] [28.8%] 
Total 
  
  
Count 30 22 52 
% within NT ProBNP 
Levels Elevation (57.7%) (42.3%) (100.0%) 
% within Angina [100.0%] [100.0%] [100.0%]  
 
 
 
 
Figure 5: Showing Percentage of incidence of recurrent anginas 
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NT-ProBNP Levels above 100 pg/ml and Angina 
 
  
 NT ProBNP Levels 
  
Angina Total 
  
P 
Value Yes No 
< 100 pg/ml 
  
  
3 11 14  
    
   
 >100 pg/ml 
 
   .001 
27 11 38  
    
        
 
 
 
60.9 % of the patients with 100-500 pg/ml of NT proBNP level 
had recurrent angina while 86.7% of the patients with NT proBNP 
values above 500 pg/ml developed recurrent angina. As the P value is 
0.001 even a 100-500 pg/ml (Moderate) elevation of NT  proBNP  
above 100pg/ml itself was a good predictor for this outcome. 
Result - There is a significant increase in incidence of recurrent angina 
in Acute Coronary Syndrome patients with NT proBNP levels above 
100 pg/ml. 
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Elevated  NT ProBNP Levels and Palpitations 
 
  
 
 
NT ProBNP Levels 
Elevation 
 
Palpitations 
Total 
 
P Value 
Yes No  
< 100 pg/ml (Min) 
 
 
Count 1 13 14  
% within Nt ProBNP 
Levels Elevation 
(7.1%) (92.9%) (100.0%) 
 
 
 
 
 
 
.015 
  % within Palpitations [7.1%] [34.2%] [26.9%] 
      
100-500 pg/ml 
(Moderate) 
Count 5 18 23 
  
% within NT ProBNP 
Levels Elevation 
(21.7%) (78.3%) (100.0%) 
 % within Palpitations [35.7%] [47.4%] [44.2%] 
 
 
>500 pg/ml 
(Marked) 
Count 8 7 15 
  
% within NT ProBNP 
Levels Elevation 
(53.3%) (46.7%) (100.0%) 
  % within Palpitations [57.1%] [18.4%] [28.8%] 
Total Count 14 38 52 
 
% within NT ProBNP 
Levels Elevation 
(26.9%) (73.1%) (100.0%) 
 % within Palpitations [100.0%] [100.0%] [100.0%]  
 
 
 
Figure 6: Incidence of palpitations in patient with different levels of NT proBNP 
Result: There is a significant positive correlation between NT proBNP 
elevation and recurrent palpitations. The P value was 0.015.  
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Elevated NT ProBNP Levels and Dyspnoea 
 
  
NT ProBNP Levels 
Elevation (pg/ml) 
  
Dyspnoea Total P 
Value 
Yes No  
< 100 pg/ml (Min) 
  
 <100 
 Count 0 14 14  
 % within NT ProBNP 
Levels Elevation 
(.0%) (100.0%) (100.0%) 
 
 % within Dyspnoea [.0%] [46.7%] [26.9%]  
100-500 
pg/ml(Moderate) 
  
 100-500 
Pg/ml 
 
 
Count 
12 11 23 
 
 % within NT ProBNP 
Levels Elevation 
(52.2%) (47.8%) (100.0%) 
.001 
 % within Dyspnoea [54.5%] [36.7%] [44.2%]  
>500 
pg/ml 
(Marked
) 
  Count 
10 5 15 
 
>500  % within NT ProBNP 
Levels Elevation 
(66.7%) (33.3%) (100.0%) 
 
  % within Dyspnoea [45.5%] [16.7%] [28.8%]  
Total Count 22 30 52  
% within NT ProBNP Levels 
Elevation 
(42.3%) (57.7%) (100.0%) 
 
% within Dyspnoea [100.0%] [100.0%] [100.0%]  
 
 
Figure 7: Chart comparing NT proBNP levels and percentage of incidence of recurrent dyspnoea in the 
follow up. 
 
Result: Dyspnoeic episodes were increasing with the level of NT 
proBNP. In chi square test the P value is 0.001 which is very significant 
at 1% level. 
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NT ProBNP Levels Elevation and Hospital Admission for Unstable Angina and 
NSTEMI 
 
  
NT ProBNP Levels Elevation 
  
  
Hospital Admissions Total 
P 
Value 
Yes No   
< 100 pg/ml (Min) 
  
  
  
Count 1 13 14  
% within NT ProBNP Levels 
Elevation 
(7.1%) (92.9%) (100.0%) 
0.009 
% within Hospital Admission [4.8%] [41.9%] [26.9%]  
  
100-500 pg/ml(Moderate) 
  
  
  
  
Count 11 12 23  
% within NT ProBNP Levels 
Elevation 
(47.8%) (52.2%) (100.0%) 
 
% within Hospital Admission 
[52.4%] [38.7%] [44.2%] 
 
  
>500 pg/ml (Marked) 
  
  
  
  
Count 9 6 15  
% within NT ProBNP Levels 
Elevation 
(60.0%) (40.0%) (100.0%) 
 
% within Hospital Admission 
[42.9%] [19.4%] [28.8%] 
 
Total 
  
  
Count 21 31 52  
% within NT ProBNP Levels 
Elevation 
(40.4%) (59.6%) (100.0%) 
 
     
 
 
 
Figure 8: Percentage of Hospital Admissions including UA and NSTEMI in patients with different NT 
proBNP levels. 
As p value is 0.009 (< 0.05) there is a significant correlation between 
elevated NT proBNP levels and rehospitalization for unstable angina 
and NSTEMI.  
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Elevated NT proBNP Levels and LV Dysfunction 
 
  
  
  
  
LV Dysfunction Total 
P value 
Deterioration 
No 
Deterioration   
  
  
  
  
  
  
  
< 100 pg/ml (Min) Count 2 12 14  
  % within NT 
ProBNP Levels 
Elevation 
(14.3%) (85.7% (100.0%) 
 
  % within LV Dysfn [8.0%] [44.4%] [26.9%]  
 
100-500 
pg/ml(Moderate) 
Count 
12 11 23 
 
  % within NT 
ProBNP Levels 
Elevation 
(52.2%) (47.8% (100.0%) 
.006 
  % within LV Dysfn [48.0%] [40.7%] [44.2%]  
 
>500 pg/ml 
(Marked) 
Count 
11 4 15 
 
  % within NT 
ProBNP  
Elevation 
(73.3%) (26.7%) (100.0%) 
 
  % within LV Dysfn [44.0%] [14.8%] [28.8%]  
      
  
   
 
      
 
 
 
Figure 9: Percentage of development of left ventricular dysfunction in ACS patients with 
elevated NT proBNP levels 
Result: 
Elevated NT ProBNP levels correlated significantly with development 
of left ventricular dysfunction in the 6 month follow up. P value was 
0.006 
0 20 40 60 80 100
< 100 pg/ml
100-500 pg/ml
> 500 pg/ml
No Deterioration
Deterioration
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Elevated NT-ProBNP Levels  and Renal Function 
  
NT ProBNP Levels 
Elevation   
  
Renal Function Total P Value 
Normal Raised   
< 100 pg/ml (Min) 
  
Count 14 0 14  
% within NT ProBNP 
Elevation (100.0%) (.0%) (100.0%) 
 
  
  
  
100-500 pg/ml(Moderate) 
% within Renal Function [30.4%] [.0%] [26.9%]  
 
 
Count 
20 3 23 
.231 
    % within NT ProBNP 
Elevation (87.0%) (13.0%) (100.0%) 
 
  
  
  
 
>500 pg/ml (Marked) 
  
  
% within Renal Function [43.5%] [50.0%] [44.2%]  
 
 
Count 
 
12 
 
3 
 
15 
 
% within NT ProBNP 
(80.0%) (20.0%) (100.0%) 
 
    % within Renal Function [26.1%] [50.0%] [28.8%]  
 
 
 
 
 
Figure 10: Percentage of patients developing elevated renal parameters in ACS with different NT proBNP 
levels 
  
       Comparing elevated NT proBNP with deterioration of renal 
function, the Pearson Chi Square test gives the P value as 0.231. So 
there is only a positive correlation of renal failure with elevated NT 
proBNP, but the correlation was not statistically significant. 
 
0
20
40
60
80
100
120
< 100 pg /ml 100 - 500 pg.ml > 500 pg/ml
Renal
Failure
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Elevated NT ProBNP Levels and Recurrent Myocardial Infarction  
 
  
NT ProBNP  Elevation 
  
  
Rec MI Total P value 
Yes No   
< 100 pg/ml (Minimal) 
  
  
  
Count 1 13 14  
% within NT ProBNP 
Elevation (7.1%) (92.9%) (100.0%) 
 
% within Rec MI [7.7%] [33.3%] [26.9%]  
  
100-500 pg/ml(Moderate) 
  
  
  
  
 
Count 
 
3 
 
20 
 
23 
 
% within NT ProBNP 
Elevation (13.0%) (87.0%) (100.0%) 
.001 
% within Rec MI [23.1%] [51.3%] [44.2%]  
  
>500 pg/ml (Marked) 
  
  
  
  
 
Count 
 
9 
 
6 
 
15 
 
% within NT ProBNP 
Elevation (60.0%) (40.0%) (100.0%) 
 
% within Rec MI [69.2%] [15.4%] [28.8%]  
Total 
  
  
Count 13 39 52  
% within NT ProBNP 
Elevation (25.0%) (75.0%) (100.0%) 
 
% within Rec MI [100.0%] [100.0%] [100.0%]  
 
 
 
 
 
 
Figure 11: Percentage of MI during follow in various NT proBNP groups 
 
        There is a significant correlation between NT proBNP elevation 
and recurrent myocardial infarction with levels > 100pg/ml. So NT 
proBNP is a good predictor of recurrent myocardial infarction in an 
ACS patient. 
0% 20% 40% 60% 80% 100%
< 100 pg/ml
100-500 pg/ml
> 500 pg/ml
No MI
MI
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Predictive Value of NT proBNP 
When NT proBNP levels were compared for the correct 
percentage of predictions the results were as follows. 
T-Test 
 
 Group Statistics 
 
  
NT ProBNP 
Levels N Mean Std. Deviation 
Std. Error 
Mean 
Risk 
TIMI Score Not elevated 14 2.07 .917 .245  
  Elevated NT 
ProBNP 
38 2.47 .893 .145 
0.159 
 
 
  
Observed outcome after 6 
months 
Predicted 
Outcome Percentage 
Correct Survived Death 
Survived 43 2 95.6 
Death 1 6 85.7 
Overall Percentage   94.2 
 
When NT proBNP level was evaluated as a risk prediction model, 
as per the Hosmer–Lemeshow statistical analysis which was used as 
goodness of fit for logistic regression models, the result obtained was 
that elevated NT proBNP levels were able to identify the outcome as 
death in 85.7 % of cases and it predicted survival in 95.6 % cases 
correctly.  
Result: Initial proBNP levels predicted mortality correctly in 85.7 % of 
cases. 
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Elevated NT-ProBNP Level  and Mortality 
 
 
NT ProBNP Elevation 
  
  
  
Outcome Total P  
Value 
Survive Death   
< 100 pg/ml (Min) 
  
  
  
  
Count 14 0 14  
% within NT ProBNP 
Elevation (100.0%) (.0%) (100.0%) 
 
% within Outcome [31.1%] [.0%] [26.9%]  
  
100-500 pg/ml(Moderate) 
  
  
  
  
 
Count 
 
21 
 
2 
 
23 
 
% within NT ProBNP 
Elevation (91.3%) (8.7%) (100.0%) 
.021 
% within Outcome [46.7%] [28.6%] [44.2%]  
  
>500 pg/ml (Marked) 
  
  
  
  
 
Count 
 
10 
 
5 
 
15 
 
% within NT ProBNP 
Elevation (66.7%) (33.3%) (100.0%) 
 
% within Outcome [22.2%] [71.4%] [28.8%]  
Total 
  
  
Count 45 7 52  
% within NT ProBNP 
Elevation (86.5%) (13.5%) (100.0%) 
 
% within Outcome [100.0%] [100.0%] [100.0%]  
 
 
 
 
 
Figure 12: Percentage of mortality in ACS patient in various NT proBNP groups. 
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In this study out of 52 ACS patients 7 patients died. It is to be 
noted that none of the patients in the group with low NT proBNP level 
died in the 6 month follow up. Out of seven patients died, two patients 
had NT proBNP level between 100 and 500 pg/ml while 5 had levels 
above 500pg/ml. Patients with elevated NT proBNP above 100 pg/ml 
had significant mortality rate as the P value was 0.021. 
Table comparing markedly elevated  NT proBNP (above 500 pg/ml) with 
mortality 
 
 
NT ProBNP Levels 
  
Mortality Total 
  
P 
Value Yes No 
<500 pg/ml 
  
  
2 35 37  
   
 
  
  
 >500 pg/ml 
 
   .003 
5 10 15  
    
        
     
     
     
 
 When the NT proBNP levels were above 500pg/ml there was 33% 
mortality rate and P value was even more significant at 0.003. But NT 
proBNP level above 100 pg/ml itself was statistically significant. Hence 
this study concluded that there is a significant correlation between the 
mortality and elevated BNP and the cutoff level can be taken as above 
100 pg/ml. 
Result: NT proBNP is a good predictor of mortality in patients with 
ACS. 
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TIMI Scoring and NT proBNP 
 
Although not being the primary objective of the study, it was 
interesting to note that risk stratification in TIMI scoring for UA & 
NSTEMI and risk stratification by NT proBNP levels were comparable. 
  
TIMI Score  and  NT-ProBNP Levels   
 
  
NT ProBNP Levels Total 
P 
Value 
Not elevated 
Elevated NT 
ProBNP   
5% 
  
  
  
  
Count 5 8 13  
% within TIMI 
Score 
(38.5%) (61.5%) (100.0%) 
 
% within NT 
ProBNP 
Levels 
[35.7%] [21.1%] [25.0%] 
 
  
8% 
  
  
  
  
Count 3 6 9  
% within TIMI 
Score 
(33.3%) (66.7%) (100.0%) 
 
% within NT 
ProBNP 
Levels 
[21.4%] [15.8%] [17.3%] .525 
   
13% 
  
  
  
  
Count 6 22 28  
% within TIMI 
Score 
(21.4%) (78.6%) (100.0%) 
 
% within NT 
ProBNP 
Levels 
[42.9%] [57.9%] [53.8%] 
 
  
20% 
  
  
  
  
Count 0 2 2  
% within TIMI 
Score 
(.0%) (100.0%) (100.0%) 
 
% within NT 
ProBNP 
Levels 
[.0%] [5.3%] [3.8%] 
 
Total Count 14 38 52  
  % within TIMI 
Score 
(26.9%) (73.1%) (100.0%) 
 
  % within NT 
ProBNP 
Levels 
[100.0%] [100.0%] [100.0%] 
 
 
In patients with ACS, NT proBNP levels did not significantly correlate 
with TIMI scoring for risk stratification in UA and NSTEMI. NT 
proBNP and TIMI scoring tend to be independent variables. Hence NT 
proBNP tends to be an independent predictor for risk and it may be 
possible to combine them. 
DISCUSSION
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DISCUSSION 
 
      The study subjects were patients with Acute Coronary Syndromes 
including Unstable Angina, NSTEMI and STEMI. All the patients 
included were less than 60 years of age. Patients with prior history of 
cardiac problems or renal failure were excluded as they might already be 
having an elevated NT proBNP level. 
A single blood sample for NT ProBNP level was taken between 2 
hours and 24 hours after the onset of symptoms.  
Out of  52 subjects 38 patients had elevated NT proBNP of more 
than 100 pg/ml. Percentage of  elevated levels were seen more in 
STEMI ( 80 %) followed by NSTEMI (66.6 %) and Unstable angina 
(57.2 %). This correlates well with other studies conducted 
(13)(14)(15)
. 
The study found no relationship between gender and NT proBNP 
levels (P Value 1.00). Other studies quote that NT proBNP is elevated 
slightly more in female sex but all those studies had included geriatric 
population 
(22)
.  
Cardiac Enzymes elevation in ACS and NT proBNP had no 
correlation (P value - 1.00) with each other. Cardiac enzymes are 
elevated only in STEMI, NSTEMI, and not in Unstable Angina. But the 
NT proBNP levels were raised in unstable angina also. NT proBNP and 
Cardiac enzymes tend to be independent variables. 
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Evaluating NT proBNP as a prognostic biomarker, this study 
found that  patients with elevated levels had recurrent symptoms and 
poor quality of life  more commonly than those with normal levels, in a 
6 month follow up period.       NT proBNP elevation was associated 
with Recurrent Angina (P value – 0.002), Palpitations (P value 
0.015), Dyspnoea (P Value – 0.001) and more frequent cardiac 
related hospital admissions including unstable angina and  NSTEMI 
(P Value - 0.009).  Patients with elevated NT proBNP levels also had 
more chances for deterioration of left ventricular function (P Value - 
0.006)  as quantified by the left ventricular ejection fraction, in the 
follow up echocardiography. 
         Patients with Elevated NT ProBNP levels ( > 100 pg / ml ) had 
another STEMI within the 6 month  follow up ( P Value – 0.001) 
when compared to those without. This is in concordance with the very 
few studies done earlier in this regard 
(6)(12)(13)
. 
          When NT proBNP levels were compared to renal function 
impairment,  there was a positive correlation. Patients with consistently 
deteriorating renal functions (6 out of 52 patients) as measured by serum 
creatinine had elevated NT proBNP level. It was however statistically 
insignificant (P Value - 0.231).  This is in contrast to other studies which 
found NT proBNP as a good predictor for deteriorating renal  
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functions
(1)(32)
. 
 
But this study population had other risk factors like 
diabetes mellitus, hypertension and atherosclerosis which could have 
contributed to the development of renal failure.  
          Initial proBNP levels predicted mortality correctly in 85.7 % of 
our cases as per Hosmer Lemeshow statistical analysis test. So NT 
proBNP has got a good positive predictive value for mortality. When 
NT proBNP was evaluated for predicting mortality, those patients with 
NT proBNP levels above  500 pg/ml had higher mortality (P Value 
0.003). When the NT proBNP level cutoff was taken as 100 pg/ml, it 
was still significantly associated with mortality (P Value – 0.021). 
Hence NT proBNP value of more than 100 pg/ml itself is a good 
predictor of mortality.  
     We compared the risk stratification of TIMI scoring for Acute 
Coronary Syndromes including Unstable Angina, NSTEMI and STEMI 
with NT proBNP levels. Both of them had good predictability 
individually. NT proBNP scoring was not superior to TIMI (P Value – 
0.525).  But the advantage was that while using NT proBNP, only a 
single blood value was necessary, avoiding the recall disadvantage of 
TIMI scoring. So NT proBNP is recommended for risk stratification in 
acute coronary syndromes. 
     We recommend further studies to combine TIMI scoring and 
NT ProBNP for an even better predictability. 
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LIMITATIONS OF THE STUDY 
 
 The major limitation of the study was the smaller number of 
subjects.  
Being a tertiary care center, the proportion of patients with more 
severe disease and multiple risk factors were getting admitted more than 
those with milder disease. So this study had more STEMI patients than 
NSTEMI or Unstable Angina patients, which is not reflecting the 
incidence pattern of the disease in the general population.   
Geriatric age group was not included specifically because NT 
proBNP levels are normally elevated in them, and the normal cut off 
values in this age group not being well defined. This will exclude a 
major portion of patients with ACS.  
Women would be developing coronary artery disease later in their 
life than the male counterpart, so in our study female subjects were 
relatively less because study excludes patients above 60 years of age. 
 
 
 
 
 
 
CONCLUSION
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CONCLUSION 
 
 NT proBNP is a reliable prognostic biomarker. 
 NT proBNP is elevated more commonly in STEMI than in NSTEMI 
or Unstable Angina 
 During follow up NT proBNP can be used to predict recurrent 
symptoms like angina, palpitations, dyspnoea, recurrent hospital 
admissions and progression to left ventricular dysfunction.  
 NT proBNP also had a good predictive value for recurrent Unstable 
Angina , NSTEMI, STEMI and cardio vascular mortality. 
 The cut off level of NT proBNP for prognostic end points can be 
taken as values  above 100 pg/ml.  
 NT proBNP levels were independent of the gender in the below 60 
age group. 
 NT ProBNP as an independent variable in risk stratification is 
comparable to TIMI risk scoring. 
 So TIMI scoring may be combined with NT proBNP for better 
prediction of cardiovascular outcome in patients with acute coronary 
syndromes. 
 
 
RECOMMENDATIONS
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RECOMMENDATIONS 
 
 
 NT proBNP should be used as a prognostic biomarker in Acute 
Coronary Syndromes. 
 More intense monitoring is required in patients with elevated NT 
proBNP levels. 
 Further studies may be undertaken to combine NT proBNP and 
TIMI scoring system for a better risk stratification in patients with 
Unstable Angina, NSTEMI and STEMI.   
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ANNEXURES 
NT ProBNP as a prognostic Biomarker in ACS – PROFORMA 
 
Name:          
Age:        
Sex:                        
IP.NO: 
Address:                              
 
Phone Number of the patient: 
Phone Number of Relatives / Neighbours : 
Presenting Complaints: 
Angina:     
Recurrent Chest Pain: 
Palpitation                                                 
Dyspnoea:                                                               
Orthopnoea:  
Oliguria: 
Co-morbid Illness:  DM □         SHT □      Dyslipidemia □         
History of prior treatment: 
Others if any: 
78 
 
EXAMINATION: 
Vital Signs:    Pulse Rate       BP           
Body Weight (in kg)        
CVS: 
RS: 
CNS 
Abdomen: 
Killips Class:  
 
Investigations For All Patients: 
     S.No Parameter Method  
1. Complete blood count Automated flow cytometry 
2. ECG 12 lead ECG 
3. Urea GLDH/urease 
4. Creatinine Picrate method 
5. Echocardiography  
6. Troponin T or CPK -MB Hs method 
8. NT ProBNP Elecsys Rapid Assay 
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Time to Treatment   <   4 hours          Yes   /   No  
TIMI Scoring:  
NT proBNP level:      
Below 100 pg/ml    □ 
100 – 500 pg/ml     □ 
Above 500 pg/ml   □      
 
DIAGNOSIS: 
 
Six Month Follow Up for Recurrent Symptoms: 
 
Chest Pain:                              Yes  /  No 
Palpitation :                              Yes /  No 
Dyspnoea :                                Yes / No 
LV Dysfunction :                      Yes / No 
Renal Dysfunction :                  Yes / No 
Hospital Admissions :              Yes / No 
Recurrent Unstable Angina :    Yes / No 
Recurrent NSTEMI :                Yes / No 
Recurrent STEMI  :                  Yes / No 
Final Outcome :                        Survived   /   Expired 
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1 Murugan 45 M Chest Pain, SOB
Smoker, 
Diabetic
1 ST elevation Elevated AWMI 4 SK
100-
500 
Normal Yes No Yes Yes Mild Lv DysfnNormal No Survived
2 Babu 56 M Chest Pain
Smoker, 
Alcoholic
0.8 T inversion Normal UA 1 Heparin
100-
500
Normal Yes No No No Mild Lv DysfnNormal No Survived
3 Perumal 55 M Giddiness SOB
DM 
Hypercholestr
olemia
1.1 ST Elevation Elevated IWMI 2 SK <100 Normal No No No No Normal Normal No Survived
4 Muniammal 48 F Chest Pain No 0.9 Non Sp Changes Normal UA 1 Heparin
100-
500
Normal No No Yes Yes Mild LV dysfnNormal No Survived
5 Balaji 55 M Chest Pain SHT 1 ST Elevation Elevated Ext AWMI 3 SK >500 Mild Lv Dys No Yes Yes Yes Mild LV dysfnNormal Yes Survived
6 Sekhar 40 M Chest Pain
SHT family 
History
0.9 ST Elevation Elevated AWMI 3 SK <100 Normal Yes Yes No Yes Mild Lv DysfnNormal No Survived
7 Mani 44 M Chest Pain
Smoker, 
Alcoholic
0.8 ST Elevation Elevated ASMI 3
SK ,elective 
PCI
>500
Mild LV 
Dys
No Yes No No Mild LV dysfnNormal No Survived
8 Jayaraj 50 M Chest Pain Alcoholic SHT 0.8 T inversion Elevated NSTEMI 2 Heparin >500 Mild Lv Dys Yes No No No Mod LV dynNormal Yes Survived
9 Nizamuddin 51 M Chest Pain SOB
Smoker Family 
Hist
1 ST Elevation Elevated IWMI 3 SK <100 Normal No No No No Normal Normal No Survived
10 Bhaskar 58 M Chest Pain SOB Smoker 1.1 ST Elevation Elevated Ext AWMI 3 SK
100-
500
Mod Lv 
Dys
Yes No Yes No Mod LV dynRaised No Survived
11 Kuppan 53 M Chest Pain Smoker 0.8 ST Elevation Elevated ASMI 3 SK >500 Mild Lv Dys Yes Yes No Yes Mild LV dysfnNormal No Survived
12 Jyothilakshmi 50 F Chest Pain SOB No 1 ST Elevation Elevated Ext AWMI 3 SK
100-
500
Normal Yes Yes Yes Yes Mild LV dysfnNormal No Survived
13 Prabhakaran 52 M
Pain Pulmonary 
Oedema
SHT Smoker 
Dyslipidemia
0.7 ST Elevation Elevated Ext AWMI 4 SK >500 Mild Lv Dys Yes Yes Yes Yes Mod LV dynNormal Yes Expired
14 Sreenivasan 39 M Chest Pain
Smoker Family 
Hist
0.9 ST Elevation Elevated AWMI 3 SK
100-
500
Normal No No No No Mild LV dysfnNormal No Survived
15 Vinod Kumar 40 M Chest Pain No 0.8 Non Sp Changes Normal UA  1
Heparin ,PCI 
elective
<100 Normal No No No No Normal Normal No Survived
Recurrent Symptoms within 6 months
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16 Karthikeyan 54 M
SOB Giddiness 
Pain
No 0.9 ST Elevation Elevated ASMI 3 SK
100-
500
RMWA
Yes No No No Mild LV dysfnNormal Yes Expired
17 Ravi 46 M Chest Pain SOB DM SHT 1 ST Elevation Elevated
Inferolatera
l MI
3 SK <100 Normal
Yes No No No Normal Normal No Survived
18 Mangammal 55 F Chest Pain DM 1 T inversion Normal UA 1 Heparin >500 Mild Lv Dys
Yes Yes Yes Yes Mod LV dynRaised Yes Survived
19 Thirumoorthy 55 M Chest Pain No 1 T inversion Normal UA 1 Heparin
100-
500
Normal
No No No No Normal Normal No Survived
20 Deen Dayal 48 M Chest Pain Smoker 0.8 T inversion Elevated NSTEMI 2 Heparin <100 Normal
Yes No No No Normal Normal Yes Survived
21 Prabhu 50 M Chest Pain SOB
Smoker 
Hypercholestr
olemia
0.8 ST elevation Elevated IWMI 3 SK
100-
500
Normal
Yes No No No Mild Lv DysfnNormal No Survived
22 Kalaiselvi 45 F Chest Pain DM 1 Non Sp Changes Normal UA 1 Heparin
100-
500
Mild Lv Dys
Yes Yes Yes Yes Mild Lv DysfnRaised No Survived
23 Jayalakshmi 56 F Chest Pain DM SHT 1 ST elevation Elevated ASMI 3 SK >500 Mild Lv Dys
Yes No Yes No Mod LV dynNormal Yes Expired
24 Seth Mohammed 55 M
SOB Giddiness 
Pain
Smoker 0.6 ST elevation High Normal
Evolved 
IWMI
3 Heparin >500 Normal
Yes No No Yes Mild LV dysfnRaised Yes Survived
25 Arumugam 55 M Chest Pain SOB Smoker SHT 0.7 ST elevation Elevated Ext AWMI 3 SK >500
Moderate 
Lv Dys Yes Yes Yes No Severe Lv Normal Yes Expired
26 Elizabeth 42 F Chest Pain DM 1 T inversion Normal UA 1 Heparin
100-
500
Moderate 
Lv Dys Yes No No Yes Severe Lv Raised No Survived
27 Chinnappaiyan 51 M Chest Pain No 0.6 T inversion Normal UA 1 Heparin <100 Normal No No No No Normal Normal No Survived
Recurrent Symptoms within 6 months
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28 Karunakaran 56 M Chest Pain
Recent CVA 
SHT 
Dyslipidemia
0.8 ST elevation Normal AWMI 3
Heparin ,PCI 
elective
100-
500
Mild Lv Dys
Yes No No No Mod LV dynNormal No Survived
29 Ayesha Beegum 58 F Chest Pain No 1 ST elevation Elevated
Evolved 
ASMI
3 Heparin <100 Mild Lv Dys
No No No No Mild Lv DysfnNormal No Survived
30 Murugan 57 M Chest Pain No 1.1 ST elevation Elevated
Inferolatera
l MI
3 SK
100-
500
Mild Lv Dys
Yes No No No Mild LV dysfnNormal No Survived
31 Geetha 50 F
SOB Giddiness 
Pain
No 0.7 Non Sp Changes Normal UA 1 Heparin <100 Normal
No No No No Normal Normal No Survived
32 Senthil Kumar 40 M Giddiness Smoker 0.7 ST elevation Elevated AWMI 2 SK
100-
500
Normal
No No No No Normal Normal No Survived
33 Anbazhagan 55 M SOBChest Pain SHT 0.5 Non Sp Changes Normal UA 1 Heparin <100 Normal
No No No No Normal Normal No Survived
34 Hari Babu 44 M Chest Pain No 0.9 ST elevation Elevated ASMI 2VD 3
SK ,elective 
PCI
<100 Normal
No No No No Normal Normal No Survived
35 Joseph 53 M Chest Pain Smoker 0.8 ST, CHB Elevated IWMI 3 SK >500 Normal
Yes No Yes Yes Mild LV dysfnRaised No Survived
36 Andal 44 F Chest Pain No 0.8 ST elevation Elevated Ext AWMI 3 SK >500 Mild Lv Dys
Yes Yes Yes Yes Mod LV dynNormal No Survived
37 Karthikeyan 52 M Chest Pain SOB Smoker 0.9 ST elevation High Normal
Evolved 
IWMI
2 Heparin
100-
500
Moderate 
Lv Dys
Yes Yes Yes Yes Mod LV dynNormal No Survived
38 Balaji 38 M Chest Pain
Smoker Family 
Hist
0.8 ST elevation Elevated AWMI 3 SK >500 Mild Lv Dys
Yes Yes Yes Yes Mod LV dynNormal No Survived
Recurrent Symptoms within 6 months
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39 Alamelu 57 F Chest Pain No 0.9 Non Sp Changes Elevated NSTEMI 2 Heparin
100-
500
Mild Lv Dys
Yes No Yes Yes Mod LV dynNormal Yes Expired
40 Elangovan 50 M Chest Pain No 0.9 Non Sp Changes Normal UA 1 Heparin
100-
500
Mild Lv Dys
Yes No No No Mod LV dynNormal No Survived
41 Kumaravel 49 M Chest Pain SHT Smoker 0.7 ST elevation Elevated IWMI 3 SK >500 Mild Lv Dys
Yes No No No Mod LV dynNormal Yes Expired
42 Santhi 55 F Abdominal Pain No 0.9 ST elevation Elevated IWMI 2 SK >500 Mild Lv Dys
Yes No Yes No Mod LV dynNormal No Survived
43 Mohan 47 M Chest pain No 1 ST elev, QS Elevated
Evolved 
ASMI
3 Heparin
100-
500
Normal No No Yes Yes Mild LV dysfnNormal No Survived
44 Lalitha 50 F Chest Pain No 0.6 Non Sp Changes Elevated UA 2 Heparin <100 Normal No No No No Normal Normal No Survived
45 Dasprakash 49 M Chest pain Smoker SHT 0.8 ST elevation Elevated
Evolved 
AWMI
3 Heparin >500
Moderate 
Lv Dys Yes No Yes Yes Severe Lv Normal Yes Expired
46 Jayakumar 48 M Chest Pain Alcoholic SHT 1 ST elevation Elevated
Inferolatera
l MI
3 SK
100-
500
Mild Lv Dys No No No No Normal Normal No Survived
47 Sasikala 56 F Chest Pain No 0.5 ST dep, T inv Normal UA 1 Heparin
100-
500
Mild Lv Dys Yes Yes Yes No Mild DysfunctionNormal Yes Survived
48 Manimegalai 55 F Chest Pain No 0.9 Non Sp Changes Normal UA 1 Heparin <100 Normal No No No No Normal Normal No Survived
49 Raja 50 M chest pain No 1 ST elevation Elevated
Evolved 
ASM
3 Heparin
100-
500
Normal No No Yes Yes Mod LV dynNormal No Survived
50 Palani 59 M Chest Pain Smoker 0.9 ST elevation Normal Evo AWMI 2 Heparin
100-
500
Mild Lv Dys No No Yes Yes Mild LV dysfnNormal No Survived
51 Parthiban 55 M Chest Pain  SHT DM 0.7 ST elevation Elevated IWMI 3 SK
100-
500
Mild Lv Dys
No Yes Yes Yes Mild LV dysfnNormal No Survived
52 Mani 42 M Chest Pain Smoker 0.8 ST elevation Elevated AWMI 3 SK <100 Normal No NO No No Normal Normal No Survived
Recurrent Symptoms within 6 months
  
Patient consent form 
 
Title 
“ROLE OF NT PRO BNP LEVELS IN PREDICTING THE PROGNOSIS IN 
ACUTE CORONARY SYNDROMES” 
 
Study Centre               : Institute of Internal Medicine, Madras Medical College 
Patient’s name : 
Patient’s age  : 
Identification number : 
 
 I confirm that I have understood the purpose of the procedures of  the above 
study. I have had the opportunity to ask questions and all my questions have been 
answered satisfactorily. 
 
           I understand that my participation in the study is entirely voluntary and that I 
am free to withdraw from the study at any time without my legal rights being 
affected            
 
I understand that sponsors of the study, others working on sponsor’s behalf, the 
ethics committee and the regulatory authorities will not need my permission 
to look at my health records both in respect of current study and any future research 
that may be conducted in relation to it; even if I withdraw from the study I agree to 
this access. However I understand that my identity will not be revealed in any 
information released to third parties unless required by law. I agree not to restrict 
the use of any data or results arising from the study. 
 
 I agree to take part in the above the study and to comply with  
the instructions given during the study and inform about any change in my health 
status to the investigator. 
 
 I hereby give permission to undergo complete clinical examination and  
investigations as part of the study. 
 
 
 
Signature of the patient       
 
 
Patient’s name and address   place   date 
 
 
Signature of the investigator       
 
 
Investigator’s name    place    date 
 
 
 
 
 
 
 
 
  
 
